
0:00
37:57
Hosts Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, welcome Dana Rizk, MD, professor of medicine in the Division of Nephrology at the University of Alabama at Birmingham. Rizk walks through the 24-month eGFR and safety findings from the phase 3 VISIONARY trial of sibeprenlimab (Voyxact) in IgA nephropathy (IgAN) in the lastest episode of Kidney Compass.
Flere episoder fra "Kidney Compass: Navigating Clinical Trials"



Gå ikke glip af nogen episoder af “Kidney Compass: Navigating Clinical Trials” - abonnér på podcasten med gratisapp GetPodcast.








